In response to the concern of increased pulmonary aspiration risk in patients under GLP-1RA treatment, the American Society of Anesthesiologists ( ASA ) has released specific recommendations to guide patient care (Joshi et al
[DOI] [PubMed] [Google Scholar] 166.Penna F., Bonetto A., Muscaritoli M., Costamagna D., Minero V.G., Bonelli G., Fanelli F.R., Baccino F.M., Costelli P
Weight loss from GLP-1 medications can result in facial volume loss, which occurs with any significant weight loss
Patients who may not be appropriate candidates include: Individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 Those with a history of severe hypersensitivity reactions to semaglutide Patients with a history of pancreatitis (relative contraindication requiring careful risk-benefit assessment) Pregnant women or those planning pregnancy (contraindicated for weight management
Watch out: strong Vitamin C or acids can deactivate copper peptides
